# Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)

> **NCT02323100** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Jewish Health** · enrollment: 16 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Ravicti low dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02323100
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-02
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** funding ended
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323100, "Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02323100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*